Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas

Shanghai Journal of Stomatology ›› 2016, Vol. 25 ›› Issue (6): 744-747.

Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas

ZHENG Jia-wei¹,WANG Xu-kai², JIANG Cheng-hong³, QIN Zhong-ping⁴, FAN Xin-dong⁵, LI Kai⁶, YANG Yao-wu⁷, HUO Ran⁸, LIU Shao-hua⁹,ZHAO Ji-hong^{10^{, WANG Xiao-yong¹¹, ZHOU De-kai¹², LEI Shao-rong¹³}}

1.Department of Oral and Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
2.Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University; Liaoning Institute of Dental Research. Shenyang 110001, Liaoning Province;
3.Department of Plastic and Reconstructive Surgery, Fujian Medical University, Union Hospital. Fuzhou 350001, Fujian Province;
4.Special Department of Hemangioma, Tumor Hospital of Linyi City. Linyi 276001, Shandong Province;
5.Department of Intervention Therapy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
6.Department of Pediatric Surgery, Children's Hospital of Fudan University. Shanghai 201102;
7.Department of Head and Neck Tumor Surgery, School of Stomatology, The Fourth Military Medical University. Xi'an 710032, Shannxi Province;
8.Department of Aesthetic Plastic and Burn Surgery, Shandong Provincial Hospital, Shandong University. Jinan 250021,Shandong Province;
10.Department of Oral and Maxillofacial Surgery, Qilu Hospital, Shandong University. Jinan 250012,Shandong Province;
10.Department of Oral Surgery, School of Stomatology, Wuhan University. Wuhan 430079, Hubei Province;
11.Department of Infantile Hemangioma, Shanghai Cao'an Hospital. Shanghai 201804；12.Department of Infantile Hemangioma, Gastrointestinal and Neonatal Surgery, Children's Hospital of Chongqing Medical University. Chongqing 400014; 13.Department of Plastic and Esthetic Surgery, Xiangya Hospital Central South University. Changsha 410008, Hunan Province, China

Received:2016-07-02 Online:2016-12-25 Published:2016-12-29

Abstract

Abstract: [Summary] Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response. To reduce the side effects caused by systemic administration of propranolol, timolol maleate treatment has been increasingly used as an alternative to systemic β-blockers and watchful waiting for many IH patients in recent years. However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial. To standardize the use of topical timolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese expert consensus on the use of topical timolol treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion, which can be used to reduce inappropriate variations in clinical practice and to promote the delivery of high quality, evidence-based health care for IH patients.

Key words: Timolol maleate, Infantile hemangioma, Expert consensus

CLC Number:

R739.8

ZHENG Jia-wei,WANG Xu-kai, JIANG Cheng-hong, QIN Zhong-ping, FAN Xin-dong, LI Ka, YANG Yao-w, HUO Ran, LIU Shao-hua,ZHAO Ji-hong, WANG Xiao-yong, ZHOU De-kai, LEI Shao-rong. Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas[J]. Shanghai Journal of Stomatology, 2016, 25(6): 744-747.

References

[1] Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature [J]. Pediatr Dermatol,2008,25(2):168-173.
[2] Waner M,Suen JY.A classification of congenital vascular lesions [C]//Waner M,Suen JY.Hemangiomas and vascular malformations of the head and neck [M].New York：Wiley-Liss,1999:1-12.
[3] Bruckner AL, Frieden IJ. Hemangiomas of infancy [J]. J Am Acad Dermatol,2003,48(4):477-493.
[4] 郑家伟.婴幼儿血管瘤“等待观察”的治疗策略应予改变[J].中国口腔颌面外科杂志,2012,10(2):163-164.
[5] 郑家伟,王绪凯,秦中平,等.口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J].上海口腔医学,2016,25(3):257-260.
[6] Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas [J]. Eur J Pediatr,2011,170(4):493-501.
[7] Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using β-blocker solution[J]. Arch Ophthalmol,2010,128(2):255-256.
[8] Ni N, Langer P, Wagner R, et al. Topical timolol for periocular hemangioma: report of further study [J]. Arch Ophthalmol, 2011,129(3):377-379.
[9] Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas [J]. Ophthal Plast Reconstr Surg, 2012,28(2):103-106.
[10] Yu L, Li S, Su B, et al. Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants [J]. Exp Ther Med, 2013,6(2):388-390.
[11] Chen ZG, Zheng JW, Yuan ML, et al. A novel topical nano-propranolol for treatment of infantile hemangiomas [J]. Nanomedicine, 2015,(11):1109-1115.
[12] Semkova K,Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas：preliminary results of a prospective study [J].Clin Exp Dermatol, 2013,38(2):143-146.
[13] 许露,刘海金,陶超,等.β受体阻滞剂局部外用治疗婴幼儿血管瘤的meta分析.中国小儿血液与肿瘤杂志,2016,21(2):60-65.
[14] Püttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas[J]. Pediatrics, 2016,138(3): e20160355.
[15] 王俞明,耿峰,查宗煜,等. 0.5%噻吗洛尔溶液局部治疗婴幼儿血管瘤的疗效观察[J].组织工程与重建外科杂志,2012,8(4):208-212.
[16] Ademola JI, Chow CA, Wester RC, et al. Metabolism of propranolol during percutaneous absorption in human skin [J]. J Pharm Sci, 1993,82(8):767-770.
[17] Lohmoller G, Frohlich ED. A comparison of timolol and propranolol in essential hypertension [J]. Am Heart J,1975,89(4):437-442.
[18] Achong MR, Piafsky KM, Ogilvie RI. Duration of cardiac effects of timolol and propranolol [J]. Clin Pharmacol Ther,1976,19(2):148-152.
[19] Coppens G, Stalmans I, Zeyen T, et al. The safety and efficacy of glaucoma medication in the pediatric population [J]. J Pediatr Ophthalmol Strabismus,2009,46(1):12-18.
[20] Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds [J]. Pediatrics,2013,131(6):e1739-1747.
[21] McMahon P, Oza V, Frieden IJ. Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic" [J]. Pediatr Dermatol,2012,29(1):127-130.
[22] 王佳,石静,王绪凯.0.5%马来酸噻吗洛尔溶液联合普萘洛尔治疗婴幼儿血管瘤的不良反应观察[J].中国口腔颌面外科杂志, 2014,12(6):539-542.
[23] Frommelt P, Juern A, Siegel D,et al.Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma [J]. Pediatr Dermatol, 2016, 33(4):405-414.
[24] 叶肖肖,金云波,林晓曦,等.外用马来酸噻吗洛尔治疗婴幼儿眼周浅表血管瘤的前瞻性研究[J].中华整形外科杂志,2011,28(3):161-162.